mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib

Wenjun Wang, Wei Bai, Enxin Wang, Yan Zhao, Lei Liu, Man Yang, Hongwei Cai, Dongdong Xia, Lei Zhang, Jing Niu, Zhanxin Yin, Zhuoli Zhang, Daiming Fan, Jielai Xia, Guohong Han*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint Dive into the research topics of 'mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib'. Together they form a unique fingerprint.

Medicine & Life Sciences